Ivabradine Tablet, Film Coated
Product Images NDC 31722-053

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ivabradine (NDC 31722-053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

5mg-60s (5mg 60s)

Label for Ivabradine Tablets 5 mg film-coated, oral dosage form. The label states 60 film-coated tablets, with NDC 31722-053-60. Manufactured for Camber Pharmaceuticals, Inc., Piscataway, NJ. Storage and dispensing instructions are included, with a barcode and manufacturer information for Annora Pharma Pvt. Ltd., Telangana, India.*

FDA Label Image

7-5mg60 (7 5mg60)

Ivabradine Tablets 7.5 mg film-coated tablet label from Camber Pharmaceuticals, Inc. The label indicates a package of 60 tablets for oral use, with storage instructions and pharmacist dispensing guidance. The label includes a barcode and manufacturer information, indicating the tablets contain 7.5 mg ivabradine equivalent.*

FDA Label Image

Camber (Camber)

FDA Label Image

Figure-4 (Figure 4)

A forest plot comparing hazard ratios (HR) with 95% confidence intervals for Ivabradine versus placebo across various subgroups including age, sex, race, cause of heart failure, weight, baseline heart rate, NYHA class, baseline LV ejection fraction, beta blocker use, aldosterone antagonist use, diabetes, and hypertension status. The horizontal axis ranges from 0.25 to 1.50, indicating whether Ivabradine or placebo is favored.*

FDA Label Image

Ivabradinetabfig2 (Ivabradinetabfig2)

A forest plot chart illustrating the fold change and 90% confidence intervals of pharmacokinetic measures (Cmax and AUC) for Ivabradine when co-administered with various strong and moderate CYP3A4 inhibitors, a CYP3A4 inducer, and other drugs. The chart includes recommendations such as 'Contraindicated' or 'Avoid Use' for specific drug interactions, and 'No Dose Adjustment' for others, comparing changes relative to Ivabradine alone.*

FDA Label Image

Ivabradinetabfig3 (Ivabradinetabfig3)

A line graph comparing the proportion of subjects with heart failure hospitalization or cardiovascular death over 36 months. Two lines represent groups receiving Ivabradine and a placebo, with subject counts at risk provided at various time points below the graph.*

FDA Label Image

Ivabradinetabstructure (Ivabradinetabstructure)

Chemical structure of ivabradine hydrochloride, showing its molecular framework with methoxy groups and ring systems, consistent with the active ingredient ivabradine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.